Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Iowa Skyrizi Prior Auth Update | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.02.74

    Skyrizi coverage and prior authorization

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.02.74 alerts

    Get alerted when Policy 05.02.74 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization requirements for risankizumab-rzaa (Skyrizi) for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It applies to members whose plans include the benefit, subject to contract exclusions, limitations, and applicable benefit terms.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicySkyrizi coverage and prior authorization
    Policy CodePolicy 05.02.74
    Change TypeNo material clinical or coverage change
    Effective DateSep 23, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for Skyrizi and document that all approval criteria are met with no exclusions to therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4FDA-approved indications addressed
    12 monthsInitial authorization duration
    12 monthsContinuation authorization duration
    6 yearsMinimum authorization age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    8 weeksIBD maintenance interval

    Coverage Criteria

    Initial Therapy — Moderate to Severe Plaque Psoriasis

    Covered when ALL of the following are met:

    ALL of the following

    • Member is 6 years of age or older.
    • ONE of the following

      • Member has previously received a biologic or targeted synthetic drug (e.g., Sotyktu, Otezla) indicated for the treatment of moderate to severe plaque psoriasis.
      • ONE of the following plaque psoriasis severity or treatment criteria

        • Crucial body areas (e.g., hands, feet, face, neck, scalp, genitals/groin, or intertriginous areas) are affected.
        • At least 10% of the body surface area (BSA) is affected.>= 10% BSA
        • ALL of the following

          • At least 3% of the BSA is affected.>= 3% BSA
          • ONE of the following

            • Member has had an inadequate response or intolerance to phototherapy (e.g., UVB or PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin.
            • Member has a clinical reason to avoid pharmacologic treatment with methotrexate, cyclosporine, and acitretin (see Appendix A).

    Initial Therapy — Active Psoriatic Arthritis

    Covered when ALL of the following are met:

    ALL of the following

    • Member is 6 years of age or older.
    • ONE of the following

      • Member has previously received a biologic or targeted synthetic drug (e.g., Rinvoq, Otezla) indicated for active psoriatic arthritis.
      • ONE of the following disease criteria

        • ALL of the following

          • Member has mild to moderate active psoriatic arthritis.
          • ONE of the following

    Initial Therapy — Crohn's Disease

    Authorization of 12 months may be granted when the requested medication is used for moderately to severely active Crohn's disease.

    Member has moderately to severely active Crohn's disease.

    Initial Therapy — Ulcerative Colitis

    Authorization of 12 months may be granted when the requested medication is used for moderately to severely active ulcerative colitis.

    Member has moderately to severely active ulcerative colitis.

    Continuation Therapy — Plaque Psoriasis

    Authorization of 12 months may be granted for all members, including new members, when ALL of the following are met:

    ALL of the following

    • Member is using the requested medication for moderate to severe plaque psoriasis.
    • Positive clinical response evidenced by ONE of the following

      • Low disease activity.
      • Improvement in signs and symptoms of the condition.
    • Improvement from baseline in ONE of the following

      • Reduction in BSA affected.

    Continuation Therapy — Psoriatic Arthritis

    Authorization of 12 months may be granted for all members, including new members, when ALL of the following are met:

    ALL of the following

    • Member is using the requested medication for psoriatic arthritis.
    • Positive clinical response evidenced by ONE of the following

      • Low disease activity.
      • Improvement in signs and symptoms of the condition.
    • Improvement from baseline in ONE or more of the following

      • Number of swollen joints.

    Continuation Therapy — Crohn's Disease

    Authorization of 12 months may be granted for all members, including new members, when ALL of the following are met:

    ALL of the following

    • Member is using the requested medication for moderately to severely active Crohn's disease.
    • ONE of the following

      • Member achieves or maintains remission.
      • ALL of the following

        • Positive clinical response evidenced by ONE of the following

          • Low disease activity.

    Continuation Therapy — Ulcerative Colitis

    Authorization of 12 months may be granted for all members, including new members, when ALL of the following are met:

    ALL of the following

    • Member is using the requested medication for moderately to severely active ulcerative colitis.
    • ONE of the following

      • Member achieves or maintains remission.
      • ALL of the following

        • Positive clinical response evidenced by ONE of the following

          • Low disease activity.

    General Requirements

    The following requirements apply to all indications:

    ALL of the following

    • For persons naïve to biologic drugs or targeted synthetic drugs associated with an increased risk of tuberculosis, the member has a documented negative tuberculosis (TB) test, which may include a TB skin test (TST) or interferon-release assay (IGRA), within 12 months before initiating therapy.
    • If TB screening is positive, further testing has confirmed that there is no active disease (e.g., chest x-ray).

      Latent TB treatment must be started before initiation of the requested medication.

    • Members currently receiving the requested medication as samples or through the manufacturer's patient assistance program must meet the criteria for initial approval.
    • Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

    Do not administer the requested medication to members with active TB infection. If latent TB disease is present, TB treatment must be started before initiation of the requested medication.

    The requested medication cannot be used concomitantly with any other biologic drug or targeted synthetic drug for the same indication.

    Skyrizi (risankizumab-rzaa) is considered not medically necessary for members who do not meet the criteria set forth above.

    Initial Therapy

    Plaque Psoriasis — Initial Authorization

    Authorization may be granted for 12 months when the member is age 6 years or older and has moderate to severe plaque psoriasis.

    Eligibility pathway

    • Prior biologic or targeted synthetic therapy: Previously received a biologic or targeted synthetic drug indicated for moderate to severe plaque psoriasis, such as Sotyktu or Otezla.
    • Severity and conventional-treatment pathway

      • Crucial body areas are affected, including the hands, feet, face, neck, scalp, genitals or groin, or intertriginous areas.
      • At least 10% of BSA is affected.>=10% BSA

    Continuation Therapy

    Plaque Psoriasis — Continuation Authorization

    Authorization may be granted for 12 months when the member achieves or maintains a positive clinical response.

    Positive clinical response: There is a reduction from baseline in affected BSA or an improvement from baseline in signs and symptoms, including itching, redness, flaking, scaling, burning, cracking, or pain.

    Psoriatic Arthritis — Continuation Authorization

    Authorization may be granted for 12 months when the member achieves or maintains a positive clinical response.

    Positive clinical response: There is improvement from baseline in swollen joints, tender joints, dactylitis, enthesitis, axial disease, skin or nail involvement, functional status, or C-reactive protein.

    Required Prior Therapy

    ConditionStep-therapy requirementAlternative qualification
    Moderate to severe plaque psoriasisFor members with at least 3% body surface area (BSA) involvement, inadequate response or intolerance to phototherapy or treatment with methotrexate, cyclosporine, or acitretin; or a documented clinical reason to avoid methotrexate, cyclosporine, and acitretin.The step-therapy requirement does not apply when crucial body areas are affected, at least 10% BSA is affected, or the member has previously received an indicated biologic or targeted synthetic drug.
    ConditionStep-therapy requirementAlternative qualification
    Mild to moderate active psoriatic arthritisInadequate response to methotrexate, leflunomide, or another conventional synthetic drug administered at an adequate dose and duration; or documented intolerance or contraindication to methotrexate, leflunomide, or another conventional synthetic drug.The member may alternatively qualify with enthesitis, severe disease, or previous treatment with an indicated biologic or targeted synthetic drug.

    Coding and Clinical Parameters

    Procedures and Billing CodesHCPCS
    J2327Skyrizi Injection, risankizumab-rzaa, intravenous, 1 mg
    Plaque Psoriasis Body Surface Area
    Extensive involvementAt least 10% of body surface area (BSA) is affected.
    Limited BSA pathwayAt least 3% BSA is affected, with the required prior-treatment failure, intolerance, or clinical reason to avoid treatment.
    Qualifying prior-treatment circumstancesFor the at least 3% BSA pathway, the member must have an inadequate response or intolerance to phototherapy, methotrexate, cyclosporine, or acitretin, or a clinical reason to avoid methotrexate, cyclosporine, and acitretin.
    Plaque Psoriasis Crucial Body Areas
    Hands and feetCrucial body areas include the hands or feet.
    Face, neck, and scalpCrucial body areas include the face, neck, or scalp.

    Quantity and Dosing Limits

    Skyrizi Quantity Limits: Plaque Psoriasis and Psoriatic Arthritis, 40 kg or Greater
    Eligible populationAdults and pediatric patients 6 years of age and older weighing 40 kg or greater with plaque psoriasis or psoriatic arthritis.
    Initiation — 75 mg presentation2 kits containing 4 x 75 mg syringes per first 28 days (4 weeks).
    Initiation — 150 mg presentation2 x 150 mg syringes or auto-injectors per first 28 days (4 weeks).
    Maintenance — 75 mg presentation1 kit containing 2 x 75 mg syringes per 84 days (12 weeks).
    Maintenance — 150 mg presentation1 x 150 mg syringe or auto-injector per 84 days (12 weeks).
    Skyrizi Quantity Limits: Pediatric Patients Weighing Less Than 40 kg

    Provider Requirements and Action Items

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Skyrizi (risankizumab-rzaa) for covered FDA-approved indications and qualifying compendial uses. Coverage is available only when all applicable approval criteria are met and no exclusion applies.

    Note

    Specialist Prescriber Required

    For initial approvals, Skyrizi must be prescribed by or in consultation with the applicable specialist.

    • Plaque psoriasis: dermatologist
    • Psoriatic arthritis: rheumatologist or dermatologist
    • Crohn's disease or ulcerative colitis: gastroenterologist
    Step Therapy

    Clinical Background

    Skyrizi (risankizumab-rzaa) is an interleukin-23 inhibitor used to treat immune-mediated inflammatory conditions, including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Coverage review considers the applicable disease severity, prior treatment history, response to ongoing therapy, tuberculosis risk, and concurrent use of biologic or targeted synthetic therapy.

    Definitions and Clinical Terms

    Policy Abbreviations and Clinical Terms
    Psoriasis and psoriatic arthritisPlaque psoriasis is a covered condition in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy; active psoriatic arthritis is covered in adults and pediatric patients 6 years of age and older.
    Crohn's disease and ulcerative colitisCovered inflammatory bowel conditions are moderately to severely active Crohn's disease and moderately to severely active ulcerative colitis in adults.
    BSABody surface area, used to measure the extent of plaque psoriasis involvement.
    TST and IGRAA tuberculosis skin test (TST) or interferon-release assay (IGRA) may be used for tuberculosis screening.
    Tuberculosis timingFor applicable biologic-naive or targeted-synthetic-drug-naive persons, a negative TB test must be documented within 12 months before initiating therapy.
    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicySkyrizi coverage and prior authorization
    Policy CodePolicy 05.02.74
    Change TypeNo material clinical or coverage change
    Effective DateSep 23, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for Skyrizi and document that all approval criteria are met with no exclusions to therapy.
    SourceLink
    On This Page
    Coverage CriteriaInitial TherapyContinuation TherapyRequired Prior TherapyCoding and Clinical ParametersQuantity and Dosing LimitsProvider Requirements and Action ItemsClinical BackgroundDefinitions and Clinical Terms
    Member has had an inadequate response to methotrexate, leflunomide, or another conventional synthetic drug (e.g., sulfasalazine) administered at an adequate dose and duration.
  1. Member has an intolerance or contraindication to methotrexate, leflunomide, or another conventional synthetic drug (e.g., sulfasalazine) (see Appendix).
  2. Member has enthesitis.
  3. Member has severe active psoriatic arthritis.
  4. Improvement in signs and symptoms, such as itching, redness, flaking, scaling, burning, cracking, or pain.
    Number of tender joints.
  5. Dactylitis.
  6. Enthesitis.
  7. Axial disease.
  8. Skin and/or nail involvement.
  9. Functional status.
  10. C-reactive protein (CRP).
  11. Improvement in signs and symptoms of the condition.
  12. Improvement from baseline in ONE or more of the following

    • Abdominal pain or tenderness.
    • Diarrhea.
    • Body weight.
    • Abdominal mass.
    • Hematocrit.
    • Appearance of the mucosa on endoscopy, computed tomography enterography (CTE), magnetic resonance enterography (MRE), or intestinal ultrasound.
    • Improvement on a disease activity scoring tool (e.g., Crohn's Disease Activity Index [CDAI] score).
  13. Improvement in signs and symptoms of the condition.
  14. Improvement from baseline in ONE or more of the following

    • Stool frequency.
    • Rectal bleeding.
    • Urgency of defecation.
    • C-reactive protein (CRP).
    • Fecal calprotectin (FC).
    • Appearance of the mucosa on endoscopy, computed tomography enterography (CTE), magnetic resonance enterography (MRE), or intestinal ultrasound.
    • Improvement on a disease activity scoring tool (e.g., Ulcerative Colitis Endoscopic Index of Severity [UCEIS] or Mayo score).
  15. At least 3% of BSA is affected and the member has had an inadequate response or intolerance to phototherapy or methotrexate, cyclosporine, or acitretin, or has a clinical reason to avoid methotrexate, cyclosporine, and acitretin.>=3% BSA

    Psoriatic Arthritis — Initial Authorization

    Authorization may be granted for 12 months when the member is age 6 years or older and has active psoriatic arthritis.

    Eligibility pathway

    • Prior biologic or targeted synthetic therapy: Previously received a biologic or targeted synthetic drug indicated for active psoriatic arthritis, such as Rinvoq or Otezla.
    • Disease-severity pathway

      • The member has mild to moderate disease and has had an inadequate response to methotrexate, leflunomide, or another conventional synthetic drug at an adequate dose and duration; has an intolerance or contraindication to one of those therapies; or has enthesitis.
      • The member has severe disease.

    Crohn's Disease — Initial Authorization

    Authorization may be granted for 12 months.

    The member has moderately to severely active Crohn's disease.Moderately to severely active disease

    Ulcerative Colitis — Initial Authorization

    Authorization may be granted for 12 months.

    The member has moderately to severely active ulcerative colitis.Moderately to severely active disease
    Genitals, groin, and intertriginous areasCrucial body areas include the genitals or groin, or intertriginous areas.
    Pediatric Weight Threshold
    40 kg or greaterThe plaque psoriasis and psoriatic arthritis quantity limits for adults and pediatric patients apply at a weight of 40 kg or greater.
    Less than 40 kgThe separate pediatric quantity limits apply to patients age 6 years and older weighing less than 40 kg.
    Clinical applicationWeight determines which Skyrizi dosing and quantity-limit schedule applies for pediatric plaque psoriasis and psoriatic arthritis.
    Tuberculosis Screening Timing
    Applicable patientsFor persons naïve to biologic drugs or targeted synthetic drugs associated with an increased risk of tuberculosis, a documented negative TB test is required.
    Acceptable testsTesting can include a tuberculosis skin test (TST) or an interferon-release assay (IGRA).
    TimingThe negative test must be obtained within 12 months of initiating therapy.
    Positive screening resultFurther testing, such as a chest x-ray, must confirm that there is no active disease; latent disease must be treated before initiation.
    Eligible populationPediatric patients age 6 years and older weighing less than 40 kg.
    Initiation2 x 55 mg syringes per first 28 days (4 weeks).
    Maintenance1 x 55 mg syringe per 84 days (12 weeks).
    Skyrizi Quantity Limits: Crohn's Disease
    IndicationCrohn's disease.
    Initiation3 vials, 600 mg per vial, per lifetime.
    Maintenance1 prefilled cartridge, 360 mg/2.4 mL, per 56 days (8 weeks).
    Skyrizi Quantity Limits: Ulcerative Colitis
    IndicationUlcerative colitis.
    Initiation6 vials, 600 mg per vial, per lifetime.
    Maintenance1 prefilled cartridge, 360 mg/2.4 mL, per 56 days (8 weeks).

    Plaque Psoriasis Prior Therapy

    For initial plaque psoriasis requests, document qualifying prior therapy or the applicable clinical pathway supporting treatment.

    • Member is age 6 or older and has previously received a biologic or targeted synthetic drug indicated for moderate to severe plaque psoriasis, such as Sotyktu or Otezla; or
    • For moderate to severe disease, document affected crucial body areas, at least 10% BSA involvement, or at least 3% BSA involvement plus inadequate response or intolerance to phototherapy or methotrexate, cyclosporine, or acitretin, or a clinical reason to avoid those pharmacologic treatments.
    Step Therapy

    Psoriatic Arthritis Prior Therapy

    For initial psoriatic arthritis requests, document qualifying prior therapy or the applicable clinical pathway supporting treatment.

    • Member is age 6 or older and has previously received a biologic or targeted synthetic drug indicated for active psoriatic arthritis, such as Rinvoq or Otezla; or
    • For mild to moderate disease, document inadequate response to methotrexate, leflunomide, or another conventional synthetic drug at an adequate dose and duration; intolerance or contraindication to these therapies; or enthesitis; or
    • Document severe active psoriatic arthritis.
    Documentation Required

    Plaque Psoriasis Documentation

    Include chart notes or medical records documenting the affected areas and body surface area (BSA) for initial plaque psoriasis requests. For continuation requests, document decreased BSA and/or improvement in signs and symptoms.

    • Initial requests: affected area(s) and BSA, if applicable
    • Initial requests: previous medications tried and response, or the clinical reason therapy is not advisable
    Documentation Required

    Psoriatic Arthritis Documentation

    For initial psoriatic arthritis requests, submit records or claims history supporting previous medications tried and response, or the clinical reason therapy is not advisable. For continuation requests, document positive clinical response.

    • Include relevant clinical details supporting the diagnosis and treatment history.
    Documentation Required

    Inflammatory Bowel Disease Documentation

    For Crohn's disease or ulcerative colitis continuation requests, submit chart notes or medical records supporting a positive clinical response to therapy or remission.

    • Relevant response measures may include abdominal pain or tenderness, diarrhea, body weight, abdominal mass, hematocrit, imaging or endoscopic mucosal findings, and improvement on a disease activity score such as CDAI.

    Unsupported block type: documentation

    Denial Risk

    Failure to Meet Criteria

    Skyrizi is not medically necessary when the applicable policy approval criteria are not met.

    • Initial and continuation requests must satisfy all applicable criteria and exclusions.
    Denial Risk

    Active or Untreated Latent Tuberculosis

    Do not administer Skyrizi to members with active tuberculosis. If latent tuberculosis is present, tuberculosis treatment must begin before Skyrizi is initiated.

    • Confirm that active TB has been excluded before treatment.
    • Initiate treatment for latent TB before starting Skyrizi.
    Denial Risk

    No Concurrent Biologic or Targeted Synthetic Therapy

    Skyrizi must not be used concomitantly with another biologic drug or targeted synthetic drug for the same indication.

    • Review the member's medication regimen before initiating or continuing therapy.
    Prior Authorization

    Samples and Patient Assistance

    Members receiving Skyrizi samples or manufacturer patient assistance must still meet the policy's initial approval criteria.

    • Sample or assistance-program access does not replace prior authorization or establish medical necessity.
    Clinical Reasons to Avoid Systemic Pharmacologic Treatment
    Alcohol and liver diseaseClinical diagnosis of alcohol use disorder, alcoholic liver disease, or other chronic liver disease.
    Drug interactionA drug interaction that makes systemic pharmacologic treatment unsuitable.
    Treatment-related toxicityRisk of treatment-related toxicity.
    Pregnancy and breastfeedingPregnancy, currently planning pregnancy, or breastfeeding.
    Significant comorbidityA significant comorbidity that prohibits systemic agents, such as liver or kidney disease, blood dyscrasias, or uncontrolled hypertension.